Dr. Pant on the Future of mCRC Treatment

Shubham Pant, MD
Published: Wednesday, Mar 28, 2018



Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

The future looks very promising. Pant notes that years ago, lung cancer was divided into non–small cell lung cancer, adenocarcinoma, squamous cell carcinoma, etc. Now, diagnoses are becoming more specific to EGFR, ALK, ROS1, and other abnormalities.

The hope is to be able to stratify CRCs the same way. Right now, there are microsatellite instability-high, and BRAF-mutated cancers. Additionally, patients with KRAS mutations need new therapies. KRAS inhibitors are in development. Combination approaches with translocations downstream of KRAS, such as RAS, RAF, MEK, ERK may be worth investigating.
 
SELECTED
LANGUAGE


Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

The future looks very promising. Pant notes that years ago, lung cancer was divided into non–small cell lung cancer, adenocarcinoma, squamous cell carcinoma, etc. Now, diagnoses are becoming more specific to EGFR, ALK, ROS1, and other abnormalities.

The hope is to be able to stratify CRCs the same way. Right now, there are microsatellite instability-high, and BRAF-mutated cancers. Additionally, patients with KRAS mutations need new therapies. KRAS inhibitors are in development. Combination approaches with translocations downstream of KRAS, such as RAS, RAF, MEK, ERK may be worth investigating.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Publication Bottom Border
Border Publication
x